<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Ann N Y Acad Sci. 2005 November ; 1058: 105&#8211;118. <br />  <br />  <br />                            Development resistance RNAi mammalian cells <br />  <br />                            Zhi-Ming Zheng*, Shuang Tang, Mingfang Tao <br />                            HIV AIDS Malignancy Branch, Center <span id='am-86' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-87' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-88'  ></span><span id='am-89' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-90' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Cancer</span> Research, National Cancer Institute, National <br />                            Institutes Health, Bethesda, MD 20892, USA <br />  <br />                            Abstract <br />                                 The discovery RNA interference (RNAi) C. elegans plants revolutionized current <br />                                 approaches biology medicine. RNAi silences genes sequence-specific manner through <br />                                 actions small pieces double-stranded RNAs (siRNAs miRNAs). RNAi found <br />                                 widespread natural phenomenon eukaryotic cells used powerful <br />                                 experimental tool explore gene function. Most importantly, potential therapeutic <br />                                 applications. Viral gene-specific siRNAs theoretically promising antiviral inhibitors and <br />                                 examined broad range medically important <span id='am-19' about='obo:NCBITaxon_10239' typeof='owl:Thing obo:NCBITaxon_1'><span id='am-20' property="oboInOwl:hasRelatedSynonym" content="viruses" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-22' property="rdfs:label" content="Viruses" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasRelatedSynonym" content="Viridae" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasRelatedSynonym" content="Vira" datatype="xsd:string"></span><span id='am-25'  ></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>viruses</span>. However, RNA viruses <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 escape RNAi-mediated suppression counteracting RNAi machinery mutation the <br />                                 targeted region, encoding viral suppressors, both. DNA viruses counteract RNAi <br />                                 machinery, preferentially using viral suppressors. Cellular factors contribute RNAi <br />                                 resistance; ADAR1 cellular factor responsible editing-mediated RNAi <br />                                 resistance. Because siRNAs used potent small-molecule inhibitors cellular gene, the <br />                                 best way cell maintain expression essential genes long-term survival develop <br />                                 program resist detrimental effects RNAi. <br />  <br />  <br />                            Keywords <br />                                 RNA interference; siRNA; miRNA; gene expression; viral inhibitors; gene therapies <br />  <br />  <br />                            INTRODUCTION <br />                                             RNA interference (RNAi) recently recognized important mechanism for <br />                                             controlling gene expression post-transcriptional level19,49 regulating heterochromatin <br />                                             formation genome stability 54,69. RNAi-mediated post-transcriptional gene silencing can <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             restrict expression certain genes tissue development cell differentiation. Small <br />                                             RNA duplexes, usually 21 23 nucleotides (nts) size, generated cleavage larger <br />                                             double-stranded (ds) RNAs ribonuclease Dicer 53,75. These small RNA duplexes trigger <br />                                             RNAi sequence-specific cleavage degradation homologous single-stranded <br />                                             mRNA suppression mRNA translation 19,28,46. <br />  <br />                                             Based origin function, small RNAs produced Dicer cleavage classified <br />                                             categories: small interfering RNAs (siRNAs) microRNAs (miRNAs). Both <br />                                             siRNAs miRNAs &#8764;21- 23-bp duplexes bearing 2-nt overhangs 3&#8242; ends. They <br />                                             differ siRNAs originate cytoplasm cleavage long dsRNAs perfect <br />                                             base-pairing26,73, miRNAs derived cleavage long, single-stranded <br />                                             primary transcripts containing imperfectly matched hairpin-loop structures. In general, primary <br />                                             miRNA transcripts cleaved RNase III-like protein Drosha &#8764;65 nt stem- <br />  <br />  <br />                            *Corresponding author: HIV AIDS Malignancy Branch, Center Cancer Research, National Cancer Institute, National Institutes <br />                            Health, 10 Center Dr., Rm. 10S 255, Bethesda, MD 20892, USA, Tel. 301-594-1382, Fax: 301-480-8250, email: <br />                            zhengt@exchange.nih.gov <br />                             Zheng et al.                                                                                               Page 2 <br />  <br />  <br />                                           loop pre-miRNAs nucleoplasm34,35 transported Exportin-5 the <br />                                           cytoplasm 44, processed Dicer &#8764;21- 23-bp miRNA duplexes <br />                                           imperfect base-pairing. For siRNAs miRNAs, strand (antisense) then <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           selectively incorporated dsRNA-induced silencing complex (RISC) contains <br />                                           Argonaute (eIF2C), SMN3, proteins 27,46,47 guides selection a <br />                                           complementary mRNA cleavage translational inhibition. Recently, Ago 2 shown <br />                                           key component cleavage substrate 27,55. The accumulated evidence far <br />                                           indicates siRNAs miRNAs program RISCs equivalently produce similar <br />                                           effects mRNA expression despite somewhat different origins 16,74. <br />  <br />                                           RNAi induced introduction synthetic &#8764;21- 23-nt siRNA duplexes cells, <br />                                           bypassing requirement processing long dsRNA mediated Dicer 20. RNAi <br />                                           mediated siRNAs miRNAs artificially introduced mammalian cells been <br />                                           successfully used knock gene expression suppress viral replication, although <br />                                           outcome individual RNAi events varies depending designed siRNAs their <br />                                           targeted regions. Efficient silencing target using RNAi approach requires active <br />                                           cell metabolism, cells undergoing exponential growth. In transient transfection <br />                                           assays synthetic siRNA duplexes, run RNAi effective dose generally confers <br />                                           detectable suppression target 48-72 hours (Fig. 1). Several runs of <br />                                           RNAi needed achieve extensive longer-lasting suppression. Although an <br />                                           individual siRNA&#8217;s half-life targeted region influence proficiency RNAi, active <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           RISC function cells necessary make suppression effective. Cells under <br />                                           exponentially active growth confer efficient up-take siRNA duplexes active <br />                                           RISC function. As shown Fig. 1, cells 96 hours culture response RNAi <br />                                           (compare lane 7 lane 6) affected siRNA-mediated p53 suppression. <br />                                           Although &#8220;RNAi resistance&#65533;? usually refers active processes, discussed below, care <br />                                           taken study RNAi RNAi resistance cells appropriate phase growth. <br />  <br />                                           Although known plant virology plant viruses to <br />                                           counteract RNAi plant cells <span id='am-119' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-120' property="rdfs:label" content="order" datatype="xsd:string"></span><span id='am-121' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>order</span> invade hosts, reports the <br />                                           development RNAi resistance mammalian cells came surprise. Approximately 22 <br />                                           silencing suppressors described plant insect viruses; been <br />                                           summarized excellent reviews 15,38,68,72. In report, emphasize the <br />                                           emergence siRNA resistance mechanism counteracts RNAi-mediated gene <br />                                           silencing mammalian cells (Table 1). <br />  <br />                               Development resistance siRNA-mediated viral gene silencing RNA <br />                               virus infections <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           RNA viruses RNA genome single-stranded double-stranded. Viral <br />                                           RNA replication infected cells mediated viral RNA-dependent RNA polymerase <br />                                           (RDRP), produces dsRNA intermediate phase single-stranded RNA viruses. <br />                                           Because lacks proofreading activity, viral RDRP replicates RNA genome low <br />                                           fidelity, resulting mutation rate order &#8764;10-4 incorporated nucleotide. That is, <br />                                           viral RDRP inherent error frequency order 1 104, depending virus <br />                                           17,36. Thus, conceivable RNA viruses selection pressure escape siRNA- <br />                                           mediated suppression mutation target regions, siRNA-resistant <br />                                           viruses. <span id='am-106' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-107' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-108' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-109' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-110'  ></span>This</span> presumption supported accumulating evidence elegant <br />                                           studies, described below. <br />  <br />                                           Using RNAi antiviral therapy considered viruses, including DNA <br />                                           viruses RNA viruses. Poliovirus tested siRNA-mediated <br />                                           sequence-specific inhibition. HeLa cells treated siRNA specific capsid protein or <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                             Page 3 <br />  <br />  <br />                                           viral polymerase infection virulent poliovirus produced 1%-3% virus <br />                                           titer observed control-treated cells showed virus plaque formation. However, the <br />                                           poliovirus readily escapes highly effective siRNAs unique point mutations within <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           targeted regions 23. The emergence siRNA-resistant viruses begins 30-40 hours <br />                                           postinfection. Further analysis resistant mutants showed RNAi recognition is <br />                                           sensitive subtle point mutations central region 3&#8242; end target RNA. <br />                                           Even single point mutation resulting G:U mismatch sufficient virus escape <br />                                           siRNA inhibition 24. Using pool siRNAs simultaneously target multiple sites the <br />                                           virus genome good choice prevent emergence resistant viruses. <br />  <br />                                           RNAi demonstrated powerful tool suppressing HIV infection various <br />                                           transient, short-term assays 11,29&#8201;33,48. Recently, resistance RNAi directed HIV-1 <br />                                           noticed siRNA duplexes targeting viral tat 1 nef 12 genes stably <br />                                           expressed human T cells long-term inhibition. RNAi-resistant HIV-1 variants been <br />                                           identified deletions substitutions siRNA target regions. Through mutations, <br />                                           HIV-1 removes RNA target escapes RNAi-mediated inhibition. <br />  <br />                                           Resistance siRNA-mediated suppression <span id='am-43' about='obo:NCBITaxon_11577' typeof='owl:Thing obo:NCBITaxon_11572 obo:NCBITaxon_1 obo:NCBITaxon_10239 obo:NCBITaxon_35305 obo:NCBITaxon_11571 obo:NCBITaxon_439488 obo:NCBITaxon_35301'><span id='am-44' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-45' property="rdfs:label" content="La Crosse virus" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasRelatedSynonym" content="Bunyavirus la crosse" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>La Crosse Virus</span> (LACV) replication also <br />                                           noticed 72 hours virus infection 293T cells pre-treated LACV siRNAs <br />                                           61. Most resistant viruses recovered culture supernatant single double <br />                                           nucleotide changes targeted regions, significantly high frequency portion <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           S segment targeted siRNA LACS103. More interestingly, viral nonstructural <br />                                           protein LACV, NSs, appears function RNAi suppressor protein. Cells expressing <br />                                           NSs protein strongly suppress RNAi directed LACV M segment host <br />                                           gene, GAPDH (glyeraldehyde-3-phosphate dehydrogenase) 61. <br />  <br />                                           The Tas protein retrovirus primate foamy virus type 1 (PFV-1) recently been <br />                                           identified suppressor miR-32, miRNA cellular origin. The PFV-1 open reading <br />                                           frame 2 contains target miR-32. As counterdefense miR-32-mediated suppression, <br />                                           PFV-1 encodes Tas silencing suppressor enables host cell invasion virus <br />                                           replication 32. <br />  <br />                               Development resistance siRNA-mediated viral gene silencing DNA <br />                               virus infections <br />                                           Compared RNA viruses, designed high rate mutation their <br />                                           RNA genome replication, genomes DNA viruses relatively stable, low <br />                                           mutation rate 10-8 10-11 incorporated nucleotide. Thus, resistance RNAi-mediated <br />                                           viral gene silencing mutation target sequence observed DNA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           virus infection. However, siRNA exert selection pressure pre-existing resistant <br />                                           mutants, exemplified recent report <span id='am-32' about='obo:NCBITaxon_10407' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_35268 obo:NCBITaxon_10239 obo:NCBITaxon_10405 obo:NCBITaxon_10404'><span id='am-33' property="rdfs:label" content="Hepatitis B virus" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasRelatedSynonym" content="human hepatitis B virus HBV" datatype="xsd:string"></span><span id='am-35'  ></span><span id='am-36' property="oboInOwl:hasRelatedSynonym" content="hepatitis B virus, HBV" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasBroadSynonym" content="HBV" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasRelatedSynonym" content="hepatitis B virus (HBV)" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasRelatedSynonym" content="hepatitis B virus HBV" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasRelatedSynonym" content="Human hepatitis B virus" datatype="xsd:string"></span>hepatitis B virus</span> (HBV) 70. HBV DNA virus, <br />                                           DNA replicates genomic RNA intermediate utilizes virally encoded <br />                                           reverse transcriptase. Consequently, significant diversity, similar seen in <br />                                           RNA viruses, occurs sequences HBV isolates; classified 8 <br />                                           genotypes (A-H). A mutant C genotype contains mutation 3&#8242; portion targeted <br />                                           region isolated resistant HBVS1 short hairpin (sh) RNA-mediated RNAi <br />                                           wild-type. This mutant preferentially selected presence HBVS1 <br />                                           shRNA Huh-7 cells co-transfected wild-type mutant HBV-C ratio 9:1 day <br />                                           5 post-transfection 70. <br />  <br />                                           Adenovirus infection result inhibition RNAi, actions a <br />                                           virally encoded noncoding RNA, VA1. Adenovirus VA1 RNA &#8764;160-nt structured RNA <br />                                           highly expressed adenovirus-infected cells (&#8764;108 molecules/cell) plays important <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                               Page 4 <br />  <br />  <br />                                           roles increasing viral mRNA translation 65 stabilizing ribosome-bound mRNAs 63, <br />                                           64. VA1 RNA enhances viral mRNA translation blocking activation protein kinase R <br />                                           (PKR), usually induced viral dsRNA produced adenoviral replication <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           cycle. <span id='am-149' about='obo:NCBITaxon_109218' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3814 obo:NCBITaxon_1 obo:NCBITaxon_72025 obo:NCBITaxon_131567 obo:NCBITaxon_3803 obo:NCBITaxon_3398 obo:NCBITaxon_163737 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-150' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-151' property="rdfs:label" content="Cullen" datatype="xsd:string"></span><span id='am-152' property="oboInOwl:hasRelatedSynonym" content="Cullen Medik." datatype="xsd:string"></span><span id='am-153'  ></span><span id='am-154' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Cullen</span> colleagues recently used reporter assay VA1 RNA inhibits <br />                                           RNAi induced shRNAs, does affect RNAi induced synthetic siRNA duplexes. <br />                                           VA1 RNA-mediated inhibition RNAi appears occur inhibition nuclear export <br />                                           shRNA, competition Exportin-5, inhibition Dicer function direct binding of <br />                                           Dicer 43. <br />  <br />                                           Our recent study shRNA-mediated oncogene silencing <span id='am-6' about='obo:NCBITaxon_10566' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_151340 obo:NCBITaxon_35237 obo:NCBITaxon_10239 obo:NCBITaxon_333774 obo:NCBITaxon_173087'><span id='am-7' property="oboInOwl:hasRelatedSynonym" content="human papillomavirus HPV" datatype="xsd:string"></span><span id='am-8' property="rdfs:label" content="Human papillomavirus" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasRelatedSynonym" content="Human Papilloma Virus" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-11'  ></span><span id='am-12' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>human papillomavirus</span> 16 <br />                                           (HPV16) cervical cancer cells provides evidence DNA virus escape RNAi <br />                                           (Tang, S., et al., unpublished <span id='am-144' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-145' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-146' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-147'  ></span><span id='am-148' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>data</span>). HPV16 contains viral oncogenes encode E6, which <br />                                           targets p53 degradation, E7, targets pRB. The oncogenes transcribed as <br />                                           single E6E7 bicistronic RNA essential genes survival cervical cancer cells. <br />                                           Transfection HPV16-positive cervical cancer cell lines, CaSki SiHa, synthetic <br />                                           siRNA duplex based sequence motif 21 nts HPV16 E6E7 bicistronic RNA <br />                                           effectively suppressed E6 E7 oncogenes, leading stabilization p53 and <br />                                           increased p21 expression. When stably expressed short hairpin RNA cells under <br />                                           selection pressure, however, siRNA silencing E6 E7 expression efficient only <br />                                           early cell passages, inefficient additional cell passages despite continued <br />                                           expression siRNA level. This loss siRNA function duplicated in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           cells stable p53 siRNA, cells stable lamin A/C siRNA, suggesting it <br />                                           target-selective. The siRNA-resistant cells retain normal siRNA processing, duplex <br />                                           unwinding degradation unwound sense strand, RISC formation, suggesting that <br />                                           loss siRNA function occurred later step. Surprisingly, siRNA-resistant cells were <br />                                           contain cytoplasmic protein &#8764;50 kDa specifically characteristically <br />                                           interacted E6E7 siRNA. These data indicate potent siRNA targeting essential <br />                                           regulatory gene induce cell develop siRNA resistance production of <br />                                           specific protein. <br />  <br />                               Viral proteins mammalian viruses function suppressors RNAi in <br />                               non-mammalian cells plants <br />                                           Several viral proteins expressed mammalian viruses, interferon antagonist proteins <br />                                           influenza virus NS1 (non-structural protein 1), reovirus &#963;3, <span id='am-13' about='obo:NCBITaxon_10245' typeof='owl:Thing obo:NCBITaxon_10240 obo:NCBITaxon_1 obo:NCBITaxon_35237 obo:NCBITaxon_10239 obo:NCBITaxon_10242 obo:NCBITaxon_10241'><span id='am-14' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasRelatedSynonym" content="vaccinia virus VV" datatype="xsd:string"></span><span id='am-16' property="rdfs:label" content="Vaccinia virus" datatype="xsd:string"></span><span id='am-17'  ></span><span id='am-18' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>vaccinia virus</span> E3L, have <br />                                           examined suppressive effects RNAi non-mammalian cells. <br />  <br />                                           Influenza viruses group single-stranded RNA viruses divided types A, B, <br />                                           C. The influenza virus NS1 protein multifunctional, non-structural protein contains <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           functional domains. Two domains N-terminal half NS1: is <br />                                           responsible translational enhancement influenza virus mRNAs interactions <br />                                           eIF4G, eukaryotic translation initiation factor, essential dsRNA- <br />                                           binding antagonizing interferon induction sequestering dsRNA PKR binding and <br />                                           activation. The domain, inhibits mRNA processing nuclear-cytoplasmic <br />                                           transport host mRNAs, C-terminal half protein 31. Using plant silencing <br />                                           suppression assay, groups simultaneously demonstrated influenza NS1 protein is <br />                                           RNA silencing suppressor plants promotes plant virus pathogenicity potato virus <br />                                           X different plant hosts 3,14. NS1 suppression RNAi requires dsRNA-binding <br />                                           domain protein functional interact siRNAs 3. These observations <br />                                           supported independent evidence Ding Palese groups showing that <br />                                           NS1 proteins influenza A, B, C viruses RNAi suppressors a <br />                                           Drosophila cell-based, nodaviral silencing screen assay. This study showed NS1 from <br />  <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                            Page 5 <br />  <br />  <br />                                           influenza A viruses suppresses RNAi Drosophila cells N-terminal dsRNA- <br />                                           binding domain binding siRNAs 39. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Reoviruses group <span id='am-155' about='obo:NCBITaxon_35325' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_10239'><span id='am-156' property="oboInOwl:hasRelatedSynonym" content="dsRNA nonenveloped viruses" datatype="xsd:string"></span><span id='am-157' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-158' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-159' property="rdfs:label" content="dsRNA viruses" datatype="xsd:string"></span>dsRNA viruses</span>. Reovirus outer shell polypeptide &#963;3 the <br />                                           best-characterized dsRNA binding proteins. Like influenza virus NS1, reovirus &#963;3 carries <br />                                           conserved dsRNA-binding motifs binds dsRNAs vitro vivo. Accordingly, <br />                                           reovirus &#963;3 protein sequesters dsRNA PKR binding prevents activation by <br />                                           dsRNA. When tested plant cells, &#963;3 showed strong RNAi suppression, failed to <br />                                           sequester miRNA precursors 40. Nevertheless, data suggest reovirus &#963;3 protein is <br />                                           capable counteracting RNAi-mediated gene silencing addition inhibiting PKR- <br />                                           mediated responses. <br />  <br />                                           Vaccinia virus member poxvirus <span id='am-83' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-84' property="rdfs:label" content="family" datatype="xsd:string"></span><span id='am-85' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>family</span> DNA genome replicates in <br />                                           cytoplasm viral infection. The vaccinia E3L protein dsRNA-binding protein <br />                                           13 inhibits PKR sequestering dsRNA PKR, preventing binding 56,59. The <br />                                           C-terminus vaccinia virus E3L responsible binding dsRNA preventing it <br />                                           activating interferon pathway. A recent study demonstrated E3L protein a <br />                                           functional suppressor RNAi Drosophila cells inactivates RNAi silencing-based <br />                                           antiviral response cells <span id='am-57' about='obo:NCBITaxon_12287' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_143920 obo:NCBITaxon_12283 obo:NCBITaxon_10239 obo:NCBITaxon_439488 obo:NCBITaxon_35278'><span id='am-58' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-60'  ></span><span id='am-61' property="rdfs:label" content="Flock house virus" datatype="xsd:string"></span>flock house virus</span> infection 39. <br />  <br />                               RNA editing plays role development siRNA resistance in <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               mammalian cells <br />                                           Double-stranded RNA induces homology-dependent degradation cognate mRNA the <br />                                           cytoplasm RNAi, target adenosine-to-inosine (A-to-I) RNA editing by <br />                                           adenosine deaminases acting RNA (ADARs). RNA editing affects siRNA-mediated <br />                                           RNAi vitro reported Chris Smith&#8217;s group 58, showed production of <br />                                           siRNAs progressively inhibited increasing deamination long dsRNA. This <br />                                           initial observation immediately supported study C. elegans showed A-to- <br />                                           I editing dsRNAs derived transgenes endogenous genes appeared to <br />                                           prevent silencing RNAi 30,67. Recent studies demonstrated direct interaction <br />                                           isoforms ADARs siRNA, which, ADAR1 ADAR2, strongly <br />                                           bind siRNA RNA editing. ADAR1p110, short form ADAR1 alternative <br />                                           translation initiation <span id='am-111' about='obo:NCBITaxon_79338' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_4130 obo:NCBITaxon_4069 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91888 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71274 obo:NCBITaxon_3193'><span id='am-112' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-113'  ></span><span id='am-114' property="rdfs:label" content="Codon" datatype="xsd:string"></span><span id='am-115' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>codon</span>, ADAR2 bound 19-bp siRNA, binding affinities <br />                                           15 50 times lower ADAR1p150 (a length ADAR1), respectively. <br />                                           ADAR3 bound longer dsRNAs, failed bind 19-bp siRNA. All ADARs were <br />                                           capable binding 19-bp siRNA (ADAR1p150 p110 ADAR2) bound siRNAs <br />                                           containing 15- 23-bp dsRNA regions. Thus, length siRNA determines <br />                                           bound siRNA edited held stable complex change sequence; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           critical size threshold appears 30 bp 71. <br />  <br />                                           The cytoplasmic full-length isoform ADAR1 highest affinity siRNA among <br />                                           known ADARs, subnanomolar dissociation constant. Gene silencing siRNA is <br />                                           significantly effective mouse fibroblasts homozygous ADAR1 null mutation <br />                                           wild-type cells. This supported suppression RNAi fibroblast <br />                                           cells overexpressing functional ADAR1, cells overexpressing mutant ADAR1 <br />                                           lacking double-stranded RNA-binding domains. The results provide convincing evidence that <br />                                           ADAR1 cellular factor limits efficacy siRNA mammalian cells 71. <br />  <br />                               Other factors lead RNAi resistance mammalian cells <br />                                           As described above, resistance RNAi viral infection mammalian cells far <br />                                           ascribed major mechanisms: mutations targeted regions expression of <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                               Page 6 <br />  <br />  <br />                                           suppressors (Table 1). One wonder viruses evolved mechanism(s) to <br />                                           counteract initiation RNAi pathway, block pathway&#8217;s intermediate <br />                                           components. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           This hypothesis received preliminary support <span id='am-62' about='obo:NCBITaxon_12475' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_10239 obo:NCBITaxon_39759'><span id='am-63' property="oboInOwl:hasRelatedSynonym" content="hepatitis delta virus HDV" datatype="xsd:string"></span><span id='am-64' property="rdfs:label" content="Hepatitis delta virus" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-66' property="oboInOwl:hasBroadSynonym" content="HDV" datatype="xsd:string"></span><span id='am-67' property="oboInOwl:hasAlternativeId" content="NCBITaxon:12682" datatype="xsd:string"></span><span id='am-68' property="oboInOwl:hasRelatedSynonym" content="Hepatitis D virus" datatype="xsd:string"></span><span id='am-69'  ></span><span id='am-70' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>hepatitis delta virus</span> (HDV) <br />                                           study. Data Taylor&#8217;s group indicate HDV RNAs resistant Dicer activity 7. <br />                                           Dicer cleaves RNAs 100% double-stranded, certain RNAs extensive <br />                                           &lt;100% pairing, release RNAs &#8764;21 nt. The circular 1,679-nt genome HDV its <br />                                           exact complement, antigenomic RNA, fold rod-like structure 74% pairing, <br />                                           resistance Dicer cleavage. In vitro cleavage assay purified recombinant <br />                                           Dicer, &lt;0.2% unit-length HDV RNAs cleaved, Dicer able digest <br />                                           fragments genome. A 66-nt hairpin RNA 79% pairing digested &gt;80% <br />                                           cleavage activity, 66-nt hairpin derived end HDV genome also <br />                                           digested. The data vitro Dicer digestion experiments consistent results <br />                                           small RNAs &#8764;21 nts detected HDV replication hepatocytes 7. That <br />                                           unit-length, highly structured HDV RNAs resist Dicer cleavage suggests viral RNAs <br />                                           evolved prevent initiation RNAi resisting Dicer. Although HDV itself be <br />                                           edited ADAR adenosine 1012 position antigenome 6,52, resistance Dicer and <br />                                           RNAi appears unrelated ADAR-mediated editing. <br />  <br />                                           The group 1,679-nt genomic antigenomic RNAs HDV are <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           resistant siRNA-mediated degradation, viral mRNAs sensitive synthetic <br />                                           siRNA duplexes. It thought base-paring HDV genomic antigenomic RNAs <br />                                           nucleus make inaccessible siRNA. However, studies show <br />                                           HDV circular RNAs transcribed DNA template host RNA polymerase II in <br />                                           Huh-7 cells, similar mRNA structure mRNAs 5&#8242; cap 3&#8242; poly A <br />                                           tail, resistant siRNA attack 8. The mechanism HDV resistant <br />                                           siRNA remains unknown. <br />  <br />                               Does siRNA activate protein kinase PKR? <br />                                           PKR, mammalian dsRNA-dependent serine-threonine protein kinase, N-terminal <br />                                           dsRNA-binding domain interact non-sequence-specifically long stretches of <br />                                           dsRNA, leading activation. The activated PKR phosphorylates inactivates translation <br />                                           factor eIF2&#8220;, resulting generalized suppression protein synthesis, followed cell death <br />                                           apoptotic nonapoptotic pathways. Activation nonspecific pathway could <br />                                           mask sequence-specific effects result RNAi pathway. Nevertheless, <br />                                           successful application RNAi reported mammalian tissue culture cell lines <br />                                           using chemically synthesized siRNAs bypass activation PKR. It been <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           documented literature small blunt-ended dsRNA 33 bp does activate <br />                                           PKR 45. In addition, early studies demonstrated siRNA-mediated inhibition gene <br />                                           expression mammalian cells independent non-specific interference pathways activated <br />                                           larger dsRNAs 5. However, recent studies indicate that, RNAi mechanism <br />                                           itself independent interferon system, transfection 21-bp siRNAs expression of <br />                                           shRNAs shRNA <span id='am-129' about='obo:NCBITaxon_29278' typeof='owl:Thing obo:NCBITaxon_81077 obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-130' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-131' property="rdfs:label" content="vectors" datatype="xsd:string"></span><span id='am-132' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>vectors</span> does trigger interferon response PKR 2,60. Thus, <br />                                           studies argue siRNAs broad complicating effects selective <br />                                           silencing target genes introduced cells. <br />  <br />                                           In effort evaluate contradictory results search possible activators PKR, <br />                                           truncated full-length versions PKR used select dsRNAs partially <br />                                           structured dsRNA library containing 1011 sequences 76. This study identified minimal RNA <br />                                           motif activation PKR. This motif hairpin nonconserved, imperfect 16-bp <br />                                           dsRNA stem flanked 11- 15-nt single-stranded tails. Boundary experiments revealed that <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                                Page 7 <br />  <br />  <br />                                           single-stranded tails flanking dsRNA core provide critical determinant for <br />                                           activation. A minimum 11 nts tails needed activation, tails could <br />                                           5&#8242;-end, 3&#8242;-end, 76. This group compared dsRNAs lengths 24, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           33, 76 bp PKR binding activation 24-bp dsRNA unable to <br />                                           activate PKR; instead, inhibited kinase. Resolution discrepancies the <br />                                           findings different study groups require additional biochemical experiments. <br />  <br />                               Closing remarks perspectives <br />                                           We entering RNAi era. The discovery RNAi C. elegans 21 plants 25 has <br />                                           revolutionized today&#8217;s approaches biology medicine. Through actions small <br />                                           pieces dsRNAs (siRNAs miRNAs), RNAi-mediated gene silencing to <br />                                           widespread natural phenomenon eukaryotes, powerful experimental <br />                                           tool explore gene function. Most importantly, potential therapeutic applications. <br />                                           Although great deal learned past years RNAi pathways the <br />                                           functions components, remains understood complete <br />                                           picture RNAi regulated mammalian cells. There absolutely doubt RNAi <br />                                           pathways, just like pathways discovered mammalian systems, subject to <br />                                           sophisticated regulation (Fig. 2). <br />  <br />                                           One RNAi function mammalian cells thought nucleic acid-based antiviral <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           immunity, evidenced recent discovery cellular miR-32 mediates antiviral <br />                                           activities human cells 32. Identification viral RNAi suppressors medically important <br />                                           RNA DNA viruses heralded beginning exploration existing anti-silencing <br />                                           mechanisms virus infection. Many RNAi suppressors identified far various RNAi <br />                                           reporter assays turn viral dsRNA binding proteins (DRBPs). Although fewer cellular <br />                                           DRBPs identified viral DRBPs, assume regulate <br />                                           endogenous miRNA siRNA functions cell needed. About 300 miRNAs <br />                                           identified genomes humans, viruses, non-human eukaryotic <span id='am-116' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-117' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-118' property="rdfs:label" content="species" datatype="xsd:string"></span>species</span>, <br />                                           abundant (&#8764; 40,000 copies/cell) 4,41,42,50,51. The question how <br />                                           examine DRBP&#8217;s suppressive function mammalian system. The suppressive functions <br />                                           viral RNA suppressors RNAi reporter assays recapitulated in vivo <br />                                           viral infections mammals. For example, NS1 <span id='am-48' about='obo:NCBITaxon_11320' typeof='owl:Thing obo:NCBITaxon_11308 obo:NCBITaxon_197911 obo:NCBITaxon_1 obo:NCBITaxon_10239 obo:NCBITaxon_439488 obo:NCBITaxon_35301'><span id='am-49' property="oboInOwl:hasBroadSynonym" content="FLUAV" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasRelatedSynonym" content="Human Influenza A Virus" datatype="xsd:string"></span><span id='am-51'  ></span><span id='am-52' property="oboInOwl:hasRelatedSynonym" content="Influenza virus type A" datatype="xsd:string"></span><span id='am-53' property="rdfs:label" content="Influenza A virus" datatype="xsd:string"></span><span id='am-54' property="oboInOwl:hasRelatedSynonym" content="influenza A virus INF A" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Influenza A virus</span> behaves effective <br />                                           RNAi suppressor Drosophila plant RNAi reporters, play role in <br />                                           siRNA-mediated inhibition animal influenza infection 22,66. <br />  <br />                                           There 388 known eukaryotic proteins dsRNA-binding domains (DRBDs), 72 <br />                                           human 37,62. More 20 DRBPs identified reported to <br />                                           function diverse range critically important roles cell, including (such as <br />                                           Dicer Ago-2) essential roles RNAi pathways 18,57. Since proteins harboring <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           DRBDs reported interact little 11 bp dsRNA, event is <br />                                           independent nucleotide sequence arrangement 57, conceivable cellular <br />                                           DRBPs actually involved switching function partially double- <br />                                           stranded miRNA that, average, targets hundreds mRNAs pairing only <br />                                           6-8 bases. ADAR1 factor type interacts siRNAs vitro limits <br />                                           efficacy siRNAs mammalian cells. <br />  <br />                                           Perhaps intriguing question natural siRNA eukaryotic <br />                                           cells virus infection. Some RNA viruses dsRNA genome others <br />                                           carry single-stranded RNA genome, produce dsRNA intermediates their <br />                                           replication. Theoretically, viral dsRNAs substrates Dicer digestion to <br />                                           produce siRNAs infected cells. However, viral dsRNAs appear resist Dicer digestion, <br />                                           exemplified HDV. This production viral siRNAs suppress viral <br />  <br />  <br />                                              Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                                   Page 8 <br />  <br />  <br />                                           gene expression harmful replication virus. Similarly, endogenous siRNA <br />                                           production human genome expected, considering 20% human <br />                                           genes produce antisense transcripts form sense-antisense pairs (dsRNA) 9, but <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           production endogenous siRNAs human transcripts beneficial for <br />                                           human gene expression. Discovering dsRNAs escape Dicer digestion another <br />                                           challenge. <br />  <br />                                           Understanding viral RNAi resistance greatly enriched knowledge regulation of <br />                                           RNAi pathways. It greatly informative know viruses escape RNAi- <br />                                           mediated inhibition counteracting mechanisms: mutations targeted <br />                                           region siRNA selection pressure and/or production RNAi suppressors. However, <br />                                           HPV16 use method develop siRNA resistance, proteins that <br />                                           appear involved siRNA resistance cells expressing HPV16 E6 E7 neither <br />                                           viral proteins ADAR1. Identification characterization proteins be <br />                                           extremely challenging, definitely guide understanding cell <br />                                           counteracts siRNA-mediated events adversely affect survival. Since siRNAs <br />                                           used potent small-molecule inhibitors cellular gene, best way cell to <br />                                           expression genes essential survival develop program to <br />                                           resist detrimental effects RNAi. <br />  <br />                               Reference List <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           1. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. <span id='am-71' about='obo:NCBITaxon_12721' typeof='owl:Thing obo:NCBITaxon_11632 obo:NCBITaxon_11652 obo:NCBITaxon_1 obo:NCBITaxon_35268 obo:NCBITaxon_10239 obo:NCBITaxon_693660 obo:NCBITaxon_327045 obo:NCBITaxon_11646'><span id='am-72' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-73'  ></span><span id='am-74' property="oboInOwl:hasBroadSynonym" content="HIV" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-76' property="rdfs:label" content="Human immunodeficiency virus" datatype="xsd:string"></span><span id='am-77' property="oboInOwl:hasRelatedSynonym" content="AIDS virus" datatype="xsd:string"></span>Human immunodeficiency virus</span> type 1 escape <br />                                              RNA interference. J. Virol 2003;77:11531&#8211;11535. [PubMed: 14557638] <br />                                           2. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction interferon response by <br />                                              RNAi vectors mammalian cells. Nat. Genet 2003;34:263&#8211;264. [PubMed: 12796781] <br />                                           3. Bucher E, Hemmes H, Haan P, Goldbach R, Prins M. The influenza A virus NS1 protein binds <br />                                              small interfering RNAs suppresses RNA silencing plants. J. Gen. Virol 2004;85:983&#8211;991. <br />                                              [PubMed: 15039540] <br />                                           4. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi&#8217;s sarcoma-associated herpesvirus <br />                                              expresses array viral microRNAs latently infected cells. Proc. Natl. Acad. Sci. U. S. A <br />                                              2005;102:5570&#8211;5575. [PubMed: 15800047] <br />                                           5. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition gene expression small <br />                                              double-stranded RNAs invertebrate vertebrate systems. Proc. Natl. Acad. Sci. U. S. A <br />                                              2001;98:9742&#8211;9747. [PubMed: 11481446] <br />                                           6. Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification adenosine the <br />                                              antigenomic RNA. J. Virol 1995;69:7593&#8211;7600. [PubMed: 7494266] <br />                                           7. Chang J, Provost P, Taylor JM. Resistance human hepatitis <span id='am-139' about='obo:NCBITaxon_998453' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_50638 obo:NCBITaxon_7438 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_7434 obo:NCBITaxon_6960 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7400 obo:NCBITaxon_33392 obo:NCBITaxon_7399 obo:NCBITaxon_34725 obo:NCBITaxon_50557'><span id='am-140' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-141' property="rdfs:label" content="Delta" datatype="xsd:string"></span><span id='am-142' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-143'  ></span>delta</span> virus RNAs dicer activity. J. <br />                                              Virol 2003;77:11910&#8211;11917. [PubMed: 14581527] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           8. Chang J, Taylor JM. Susceptibility human hepatitis delta virus RNAs small interfering RNA <br />                                              action. J. Virol 2003;77:9728&#8211;9731. [PubMed: 12915586] <br />                                           9. Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, Zhou G, Shi RZ, Rowley JD. Over 20% human <br />                                              transcripts form sense-antisense pairs. Nucleic Acids Res 2004;32:4812&#8211;4820. [PubMed: <br />                                              15356298] <br />                                           10. Child SJ, Hakki M, De Niro KL, Geballe AP. Evasion cellular antiviral responses human <br />                                                <span id='am-27' about='obo:NCBITaxon_10358' typeof='owl:Thing obo:NCBITaxon_10357 obo:NCBITaxon_1 obo:NCBITaxon_548681 obo:NCBITaxon_35237 obo:NCBITaxon_10239 obo:NCBITaxon_10292'><span id='am-28' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-30'  ></span><span id='am-31' property="rdfs:label" content="Cytomegalovirus" datatype="xsd:string"></span>cytomegalovirus</span> TRS1 IRS1. J. Virol 2004;78:197&#8211;205. [PubMed: 14671101] <br />                                           11. Coburn GA, Cullen BR. Potent specific inhibition human immunodeficiency virus type 1 <br />                                                replication RNA interference. J. Virol 2002;76:9225&#8211;9231. [PubMed: 12186906] <br />                                           12. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. Human <br />                                                immunodeficiency virus type 1 escapes RNA interference-mediated inhibition. J. Virol <br />                                                2004;78:2601&#8211;2605. [PubMed: 14963165] <br />                                           13. Davies MV, Chang HW, Jacobs BL, Kaufman RJ. The E3L K3L vaccinia virus gene products <br />                                                stimulate translation inhibition double-stranded RNA-dependent protein kinase by <br />                                                different mechanisms. J. Virol 1993;67:1688&#8211;1692. [PubMed: 8094759] <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                                    Page 9 <br />  <br />  <br />                                           14. Delgadillo MO, Saenz P, Salvador B, <span id='am-78' about='obo:NCBITaxon_316718' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_3646 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_235631 obo:NCBITaxon_3977 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_91835 obo:NCBITaxon_235892 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-79'  ></span><span id='am-80' property="rdfs:label" content="Garcia" datatype="xsd:string"></span><span id='am-81' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-82' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Garcia</span> JA, Simon-Mateo C. Human influenza virus NS1 protein <br />                                               enhances viral pathogenicity acts RNA silencing suppressor plants. J. Gen. Virol <br />                                               2004;85:993&#8211;999. [PubMed: 15039541] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           15. Ding SW, Li H, Lu R, Li F, Li WX. RNA silencing: conserved antiviral immunity plants and <br />                                               animals. Virus Res 2004;102:109&#8211;115. [PubMed: 15068886] <br />                                           16. Doench JG, Petersen CP, Sharp PA. siRNAs function miRNAs. Genes Dev 2003;17:438&#8211;442. <br />                                               [PubMed: 12600936] <br />                                           17. Dougherty JP, Temin HM. Determination rate base-pair substitution insertion mutations <br />                                               retrovirus replication. J. Virol 1988;62:2817&#8211;2822. [PubMed: 2839703] <br />                                           18. Doyle M, Jantsch MF. New old roles double-stranded RNA-binding domain. J. Struct. Biol <br />                                               2002;140:147&#8211;153. [PubMed: 12490163] <br />                                           19. Dykxhoorn DM, Novina CD, Sharp PA. Killing messenger: short RNAs silence gene <br />                                               expression. Nat. Rev. Mol. Cell Biol 2003;4:457&#8211;467. [PubMed: 12778125] <br />                                           20. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes 21-nucleotide <br />                                               RNAs mediate RNA interference cultured mammalian cells. Nature 2001;411:494&#8211;498. [PubMed: <br />                                               11373684] <br />                                           21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent specific genetic <br />                                               interference double-stranded RNA <span id='am-91' about='obo:NCBITaxon_6239' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6237 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-92' property="oboInOwl:hasExactSynonym" content="roundworm" datatype="xsd:string"></span><span id='am-93' property="rdfs:label" content="Caenorhabditis elegans" datatype="xsd:string"></span><span id='am-94'  ></span><span id='am-95' property="oboInOwl:hasRelatedSynonym" content="Rhabditis elegans" datatype="xsd:string"></span><span id='am-96' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-97' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Caenorhabditis elegans</span>. Nature 1998;391:806&#8211;811. <br />                                               [PubMed: 9486653] <br />                                           22. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition influenza virus production virus- <br />                                               infected mice RNA interference. Proc. Natl. Acad. Sci. U. S. A 2004;101:8676&#8211;8681. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               15173599] <br />                                           23. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in <br />                                               human cells. Nature 2002;418:430&#8211;434. [PubMed: 12087357] <br />                                           24. Gitlin L, Stone JK, Andino R. Poliovirus escape RNA interference: short interfering RNA-target <br />                                               recognition implications therapeutic approaches. J. Virol 2005;79:1027&#8211;1035. [PubMed: <br />                                               15613331] <br />                                           25. Hamilton AJ, Baulcombe DC. A species small antisense RNA posttranscriptional gene silencing <br />                                               plants. Science 1999;286:950&#8211;952. [PubMed: 10542148] <br />                                           26. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post- <br />                                               transcriptional gene silencing Drosophila cells. Nature 2000;404:293&#8211;296. [PubMed: 10749213] <br />                                           27. Hammond SM, Boettcher S, Caudy <span id='am-133' about='obo:NCBITaxon_152839' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_158359 obo:NCBITaxon_158331 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158350 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-134' property="oboInOwl:hasRelatedSynonym" content="Aa Rchb.f." datatype="xsd:string"></span><span id='am-135' property="rdfs:label" content="Aa" datatype="xsd:string"></span><span id='am-136' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-137' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-138'  ></span>AA</span>, Kobayashi R, Hannon GJ. Argonaute2, link genetic <br />                                               biochemical analyses RNAi. Science 2001;293:1146&#8211;1150. [PubMed: 11498593] <br />                                           28. Hannon GJ. RNA interference. Nature 2002;418:244&#8211;251. [PubMed: 12110901] <br />                                           29. Jacque JM, Triques K, Stevenson M. Modulation HIV-1 replication RNA interference. Nature <br />                                               2002;418:435&#8211;438. [PubMed: 12087358] <br />                                           30. Knight SW, Bass BL. The role RNA editing ADARs RNAi. Mol. Cell 2002;10:809&#8211;817. <br />                                               [PubMed: 12419225] <br />                                           31. Krug RM, Yuan W, Noah DL, Latham AG. Intracellular warfare human influenza viruses <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               human cells: roles viral NS1 protein. Virology 2003;309:181&#8211;189. [PubMed: <br />                                               12758165] <br />                                           32. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib A, Voinnet O. A <br />                                               cellular microRNA mediates antiviral defense human cells. Science 2005;308:557&#8211;560. [PubMed: <br />                                               15845854] <br />                                           33. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J. Expression small <br />                                               interfering RNAs targeted HIV-1 rev transcripts human cells. Nat. Biotechnol <br />                                               2002;20:500&#8211;505. [PubMed: 11981565] <br />                                           34. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The <br />                                               nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415&#8211;419. [PubMed: <br />                                               14508493] <br />                                           35. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing subcellular <br />                                               localization. EMBO J 2002;21:4663&#8211;4670. [PubMed: 12198168] <br />  <br />  <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                                    Page 10 <br />  <br />  <br />                                           36. Leider JM, Palese P, Smith FI. Determination mutation rate retrovirus. J. Virol <br />                                               1988;62:3084&#8211;3091. [PubMed: 2841464] <br />                                           37. Letunic I, Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, Ponting CP, Bork P. SMART <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               4.0: genomic data integration. Nucleic Acids Res 2004;32:D142&#8211;D144. [PubMed: <br />                                               14681379] <br />                                           38. Li WX, Ding SW. Viral suppressors RNA silencing. Curr. Opin. Biotechnol 2001;12:150&#8211;154. <br />                                               [PubMed: 11287229] <br />                                           39. Li WX, Li H, Lu R, Li F, Dus M, Atkinson P, Brydon EW, Johnson KL, Garcia-Sastre A, Ball LA, <br />                                               Palese P, Ding SW. Interferon antagonist proteins influenza vaccinia viruses suppressors <br />                                               RNA silencing. Proc. Natl. Acad. Sci. U. S. A 2004;101:1350&#8211;1355. [PubMed: 14745017] <br />                                           40. Lichner Z, Silhavy D, Burgyan J. Double-stranded RNA-binding proteins suppress RNA <br />                                               interference-mediated antiviral defences. J. Gen. Virol 2003;84:975&#8211;980. [PubMed: 12655099] <br />                                           41. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science <br />                                               2003;299:1540. [PubMed: 12624257] <br />                                           42. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP. The <br />                                               microRNAs <span id='am-98' about='obo:NCBITaxon_6237' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_119089 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_55879 obo:NCBITaxon_131567 obo:NCBITaxon_55885 obo:NCBITaxon_6236 obo:NCBITaxon_33154 obo:NCBITaxon_6231 obo:NCBITaxon_1206794 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6243 obo:NCBITaxon_6072'><span id='am-99' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-101'  ></span><span id='am-102' property="rdfs:label" content="Caenorhabditis" datatype="xsd:string"></span>Caenorhabditis</span> elegans. Genes Dev 2003;17:991&#8211;1008. [PubMed: 12672692] <br />                                           43. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA inhibit small interfering RNA MicroRNA <br />                                               biogenesis. J. Virol 2004;78:12868&#8211;12876. [PubMed: 15542639] <br />                                           44. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export microRNA precursors. <br />                                               Science 2004;303:95&#8211;98. [PubMed: 14631048] <br />                                           45. Manche L, Green SR, Schmedt C, Mathews MB. Interactions double-stranded RNA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               regulators protein kinase DAI. Mol. Cell Biol 1992;12:5238&#8211;5248. [PubMed: 1357546] <br />                                           46. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs <br />                                               guide target RNA cleavage RNAi. Cell 2002;110:563&#8211;574. [PubMed: 12230974] <br />                                           47. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss <br />                                               G. miRNPs: novel <span id='am-103' about='obo:NCBITaxon_class' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-104' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-105' property="rdfs:label" content="class" datatype="xsd:string"></span>class</span> ribonucleoproteins containing numerous microRNAs. Genes Dev <br />                                               2002;16:720&#8211;728. [PubMed: 11914277] <br />                                           48. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman <br />                                               J, Shankar P, Sharp PA. siRNA-directed inhibition HIV-1 infection. Nat. Med 2002;8:681&#8211;686. <br />                                               [PubMed: 12042777] <br />                                           49. Novina CD, Sharp PA. The RNAi revolution. Nature 2004;430:161&#8211;164. [PubMed: 15241403] <br />                                           50. Pfeffer S, Sewer A, Lagos-<span id='am-1' about='obo:NCBITaxon_417473' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_123369 obo:NCBITaxon_33154 obo:NCBITaxon_1489908 obo:NCBITaxon_123367 obo:NCBITaxon_123368 obo:NCBITaxon_123365 obo:NCBITaxon_123366 obo:NCBITaxon_1489872 obo:NCBITaxon_2759 obo:NCBITaxon_8087 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_28738 obo:NCBITaxon_1489388 obo:NCBITaxon_586240 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_1489913 obo:NCBITaxon_7898 obo:NCBITaxon_32443 obo:NCBITaxon_41665 obo:NCBITaxon_8079'><span id='am-2'  ></span><span id='am-3' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-4' property="rdfs:label" content="Quintana" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Quintana</span> M, Sheridan R, <span id='am-122' about='obo:NCBITaxon_283033' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_7742 obo:NCBITaxon_89593 obo:NCBITaxon_641308 obo:NCBITaxon_117571 obo:NCBITaxon_8165 obo:NCBITaxon_123369 obo:NCBITaxon_33154 obo:NCBITaxon_123367 obo:NCBITaxon_123368 obo:NCBITaxon_123365 obo:NCBITaxon_123366 obo:NCBITaxon_1489922 obo:NCBITaxon_1489872 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_8111 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_1489388 obo:NCBITaxon_8112 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_7898 obo:NCBITaxon_32443 obo:NCBITaxon_41665'><span id='am-123'  ></span><span id='am-124' property="rdfs:label" content="Sander" datatype="xsd:string"></span><span id='am-125' property="oboInOwl:hasRelatedSynonym" content="Stizostedion" datatype="xsd:string"></span><span id='am-126' property="oboInOwl:hasAlternativeId" content="NCBITaxon:54345" datatype="xsd:string"></span><span id='am-127' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-128' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Sander</span> C, Grasser FA, van Dyk LF, Ho CK, <br />                                               Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan <br />                                               M, Tuschl T. Identification microRNAs herpesvirus family. Nat. Methods 2005;2:269&#8211;276. <br />                                               [PubMed: 15782219] <br />                                           51. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, <br />                                               Tuschl T. Identification virus-encoded microRNAs. Science 2004;304:734&#8211;736. [PubMed: <br />                                               15118162] <br />                                           52. Polson AG, Bass BL, Casey JL. RNA editing hepatitis delta virus antigenome dsRNA-adenosine <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               deaminase. Nature 1996;380:454&#8211;456. [PubMed: 8602246] <br />                                           53. Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, Radmark O. Ribonuclease activity and <br />                                               RNA binding recombinant human Dicer. EMBO J 2002;21:5864&#8211;5874. [PubMed: 12411504] <br />                                           54. Provost P, Silverstein RA, Dishart D, Walfridsson J, Djupedal I, Kniola B, Wright A, Samuelsson B, <br />                                               Radmark O, Ekwall K. Dicer required chromosome segregation gene silencing fission <br />                                               yeast cells. Proc. Natl. Acad. Sci. U. S. A 2002;99:16648&#8211;16653. [PubMed: 12482946] <br />                                           55. Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification Argonaute 2 sole <br />                                               protein required RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. U. S. A <br />                                               2004;101:14385&#8211;14389. [PubMed: 15452342] <br />                                           56. Romano PR, Zhang F, Tan SL, Garcia-Barrio MT, Katze MG, Dever TE, Hinnebusch AG. Inhibition <br />                                               double-stranded RNA-dependent protein kinase PKR vaccinia virus E3: role complex <br />                                               formation E3 N-terminal domain. Mol. Cell Biol 1998;18:7304&#8211;7316. [PubMed: 9819417] <br />                                           57. Saunders LR, Barber GN. The dsRNA binding protein family: critical roles, diverse cellular functions. <br />                                               FASEB J 2003;17:961&#8211;983. [PubMed: 12773480] <br />  <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                                    Page 11 <br />  <br />  <br />                                           58. Scadden AD, Smith CW. RNAi antagonized A--&gt;I hyper-editing. EMBO Rep 2001;2:1107&#8211; <br />                                               1111. [PubMed: 11743024] <br />                                           59. Sharp TV, Moonan F, Romashko A, Joshi B, Barber GN, Jagus R. The vaccinia virus E3L gene <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               product interacts regulatory substrate binding regions PKR: implications for <br />                                               PKR autoregulation. Virology 1998;250:302&#8211;315. [PubMed: 9792841] <br />                                           60. Sledz CA, Holko M, Veer MJ, Silverman RH, Williams BR. Activation interferon system <br />                                               short-interfering RNAs. Nat. Cell Biol 2003;5:834&#8211;839. [PubMed: 12942087] <br />                                           61. Soldan SS, Plassmeyer ML, Matukonis MK, Gonzalez-Scarano F. La Crosse virus nonstructural <br />                                               protein NSs counteracts effects short interfering RNA. J. Virol 2005;79:234&#8211;244. [PubMed: <br />                                               15596819] <br />                                           62. Stefl R, Skrisovska L, Allain FH. RNA sequence- shape-dependent recognition proteins in <br />                                               ribonucleoprotein particle. EMBO Rep 2005;6:33&#8211;38. [PubMed: 15643449] <br />                                           63. Strijker R, Fritz DT, Levinson AD. Adenovirus VAI-RNA regulates gene expression controlling <br />                                               stability ribosome-bound RNAs. EMBO J 1989;8:2669&#8211;2675. [PubMed: 2583126] <br />                                           64. Svensson C, Akusjarvi G. A novel effect adenovirus VA RNA1 cytoplasmic mRNA abundance. <br />                                               Virology 1990;174:613&#8211;617. [PubMed: 2106186] <br />                                           65. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. Adenovirus VAI RNA required for <br />                                               efficient translation viral mRNAs late times infection. Cell 1982;31:543&#8211;551. [PubMed: <br />                                               6297772] <br />                                           66. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection lethal influenza virus challenge <br />                                               RNA interference vivo. Proc. Natl. Acad. Sci. U. S. A 2004;101:8682&#8211;8686. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               15173583] <br />                                           67. Tonkin LA, Bass BL. Mutations RNAi rescue aberrant chemotaxis ADAR mutants. Science <br />                                               2003;302:1725. [PubMed: 14657490] <br />                                           68. Voinnet O. Induction suppression RNA silencing: insights viral infections. Nat. Rev. <br />                                               Genet 2005;6:206&#8211;220. [PubMed: 15703763] <br />                                           69. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA. Regulation heterochromatic <br />                                               silencing histone H3 lysine-9 methylation RNAi. Science 2002;297:1833&#8211;1837. [PubMed: <br />                                               12193640] <br />                                           70. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT, Hsu YW, Lu CY, Chen DS, Chen PJ. <br />                                               RNA interference-mediated control hepatitis B virus emergence resistant mutant. <br />                                               Gastroenterology 2005;128:708&#8211;716. [PubMed: 15765406] <br />                                           71. Yang W, Wang Q, Howell KL, Lee JT, Cho DS, Murray JM, Nishikura K. ADAR1 RNA deaminase <br />                                               limits short interfering RNA efficacy mammalian cells. J. Biol. Chem 2005;280:3946&#8211;3953. <br />                                               [PubMed: 15556947] <br />                                           72. Zamore PD. Plant RNAi: How viral silencing suppressor inactivates siRNA. Curr. Biol <br />                                               2004;14:R198&#8211;R200. [PubMed: 15028237] <br />                                           73. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs ATP-dependent <br />                                               cleavage mRNA 21 23 nucleotide intervals. Cell 2000;101:25&#8211;33. [PubMed: 10778853] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           74. Zeng Y, Yi R, Cullen BR. MicroRNAs small interfering RNAs inhibit mRNA expression by <br />                                               similar mechanisms. Proc. Natl. Acad. Sci. U. S. A 2003;100:9779&#8211;9784. [PubMed: 12902540] <br />                                           75. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer preferentially cleaves dsRNAs <br />                                               termini requirement ATP. EMBO J 2002;21:5875&#8211;5885. [PubMed: 12411505] <br />                                           76. Zheng X, Bevilacqua PC. Activation protein kinase PKR short double-stranded RNAs with <br />                                               single-stranded tails. RNA 2004;10:1934&#8211;1945. [PubMed: 15547138] <br />  <br />  <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                             Page 12 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Fig. 1. <br />                                           RNAi mediated synthetic siRNA duplexes depends active cell growth. Efficiencies of <br />                                           synthetic p53 siRNA non-specific (NS) siRNA duplexes cellular p53 expression were <br />                                           assayed CaSki cells 2 &#215; 105 20-24 hours (0 time) plating transient transfection <br />                                           using oligofactamine (Invitrogen). Cell samples prepared 24, 48, 72, 96, 120 <br />                                           hours transfection siRNA (20 nM) diagramed examined Western <br />                                           blot p53 using anti-p53 antibody (Oncogene). Cells (lane 7) (lane 6) re- <br />                                           transfection NS p53 siRNAs 96 hours initial siRNA transfection, as <br />                                           indicated diagram above, compared showed difference responding <br />                                           p53 siRNAs 120 h post initial transfection. <br />  <br />  <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                             Zheng et al.                                                                                     Page 13 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Fig. 2. <br />                                           RNAi pathways RNAi resistance. Despite different origins, siRNA and <br />                                           microRNA similar effects mRNA expression RISC-mediated activities. <br />                                           Development RNAi resistance mammalian cells possible blocks <br />                                           (-) RNAi pathways. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Ann N Y Acad Sci. Author manuscript; available PMC 2006 May 17. <br />                                  Zheng et al.                                                                                                   Page 14 <br />  <br />                                                                                              Table 1. <br />                                 Mechanisms development resistance RNAi mammalian cells <br />  <br />                            RNAi-resistance by*                      Mutation target           Production suppressors   Cellular proteins <br />                                                                           regions <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            RNA viruses <br />                            Poliovirus                                        Yes <br />                            HIV-1                                             Yes <br />                            La Crosse                                         Yes                               NSs <br />                            PFV-1                                                                               Tas <br />                            Influenza                                 <br /> </body></html>